CA-DOCTOR-EVIDENCE/DRE
2.6.2020 16:02:12 CEST | Business Wire | Press release
DRE is pleased to welcome Joe Boystak as Chairman of the Board and Ameet Nathwani, MD, as Chairman of its newly formed Medical Strategy Advisory Board (MSAB). These enhancements to the Company reflect the expanded need for keen guidance in this unprecedented time of convergence between expert AI-enabled technology in healthcare and the exponential growth of clinical information. DRE is dedicated to applying sophisticated data science with advanced AI to generate quicker, deeper, more nuanced regulatory-grade scientific and clinical insights for the betterment of patient outcomes.
Boystak is an experienced healthcare venture capitalist and senior healthcare investment banker having been Founding Managing Partner at Health2047 Capital Partners and Founding Managing Director, Global Life Sciences at Jefferies. He is CEO of Brightwaters Capital and is a serial co-founder/investor in biomedical, med tech, health information technology, and artificial intelligence companies with spinouts from UCLA, Johns Hopkins, Harvard/Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, among others. Boystak is also named co-inventor on 5 issued US/EU patents for first-in-class medical technology developed by Bruin Biometrics LLC, a company he co-founded and was its initial Chairman. He has served on more than a dozen corporate and non-profit boards and currently serves on the Johns Hopkins Bloomberg School of Public Health and Southern California Biomedical Council (SoCalBio) Boards.
“I am honored to join the DRE Board as its Chairman. DRE’s industry leading SaaS platform is facilitating AI-driven drug discovery as pharma and life sciences companies rapidly adopt this technology,” stated Boystak. “Our SaaS platform enables, among others, researchers and drug developers to optimize drug design, improve clinical trial effectiveness, rapidly explore repurposing of compounds, refine FDA label strategies and improve product life cycle management - thus creating substantial ROI for our clients.”
Ameet Nathwani, MD, is Chairman of the newly created MSAB, which will initially consist of five members that represent industry, specialty medical societies, regulatory, data science and patient advocacy. Dr. Nathwani’s most recent position as Executive Vice President, Chief Medical Officer and Chief Digital Officer at Sanofi provides a great framework for the MSAB to inform DRE on strategy, regulatory requirements, research and development, technology and trends in clinical care. The MSAB will also advise on healthcare ecosystem partners for DRE to collaborate with to accelerate treatments and cures.
“It is a privilege to be appointed as the Chairman of the DRE MSAB. At a time when the volume and complexity of scientific data is increasing exponentially, the AI-driven DRE platform provides a state-of-the-art tool which gives healthcare organizations the ability to deconvolute critical scientific data. This agile approach to make rigorous and rapid decisions of real-world data is critical to innovate in this dynamic century of biology,” said Ameet Nathwani, MD. “The MSAB will advise DRE on enhancing the many scientific and healthcare applications of the platform in order to best support a diverse spectrum of partners that will ultimately benefit physicians and patients.”
“With our expanded SaaS platform now including the launch of DOC Analytics ™ we are that much closer to achieving our mission of democratizing sophisticated analysis of clinical studies and real-world data for researchers,” added Bob Battista, MBA, FRCPH, FRCP Edin. “We have been fortunate to be backed by a committed group of investors and Board members that Joe will now lead as we chart our next stage of growth. We are similarly privileged to have Dr. Nathwani lead our newly established MSAB. Ameet’s deep sector knowledge and passion for DRE’s SaaS platform provide an incredible basis for guiding our healthcare strategy.”
Joe Boystak and Ameet Nathwani, MD, join a distinguished group of Corporate Board members at DRE that include: Marc Rapaport, immediate past Chairman of DRE, immediate past Chairman of the Board of Cedars-Sinai Medical Center (Los Angeles), private equity investor, and former Executive Vice President and Co-Head of Capital Markets at Drexel Burnham Lambert and Jefferies; Vivek Garipalli, CEO and Co-Founder Clover Health, Co-Founder CarePoint Health, and an active investor in early stage healthcare companies, including founding investor in Flatiron; Ted Meisel, serial healthcare and technology entrepreneur, Executive Founder of AVIA, Executive Chairman of WiserCare, Senior Advisor NextEquity Partners, past Senior Advisor to the Center for Medicare and Medicaid Services (CMS), past President Yahoo Search and past CEO of Overture (acquired by Yahoo); Ananth Bhogaraju, Founder and Managing Director Seven Hills Healthcare Advisors and past Vice Chairman Americas Healthcare Investment Banking Deutsche Bank; Larry Burstein, a healthcare focused Family Office career fund manager; Bob Battista, Co-Founder and CEO DRE, serial healthcare and technology entrepreneur, past Executive Vice President at TheraCom, the first ever specialty pharmacy; and Todd Feinman, MD, Co-Founder and Chief Medical Officer DRE, Hospitalist at Cedars-Sinai Medical Center (Los Angeles) and Director of a large Independent Physician Association.
ABOUT DRE
DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable insights. DRE provides instant, continuous search and data analysis across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their clinical programs. Its technology platform provides DRE's customers with a Software-as-a-Service ("SaaS") Insights Engine which empower them to make better decisions from lab to patient.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005298/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mobix Labs Signs Definitive Agreement to Acquire Vision Aerial, Accelerating Global Drone Platform for National Security and Aerial Intelligence24.7.2026 13:00:00 CEST | Press release
Transaction accelerates Mobix Labs’ global aerial intelligence strategy and National Security Matters Initiative Mobix Labs, Inc. (Nasdaq: MOBX) today announced that it has signed a definitive agreement to acquire Vision Aerial, Inc., a U.S.-based designer and manufacturer of American-built, National Defense Authorization Act (NDAA)-compliant unmanned aerial systems. The definitive agreement moves the transaction beyond the previously announced letter of intent and represents a major step toward closing an acquisition that would expand Mobix Labs into one of the world’s most important technology growth markets: secure drones, autonomous aerial systems and aerial intelligence for national security, critical infrastructure, energy, public safety, industrial inspection and government operations. Vision Aerial’s customers and end-users include the U.S. Air Force, U.S. Navy, government agencies, energy and utility operators, research institutions and other organizations requiring performanc
Enhertu® Plus Pertuzumab Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with HER2 Positive Metastatic Breast Cancer24.7.2026 13:00:00 CEST | Press release
Recommendation based on DESTINY-Breast09 phase 3 trial results that showed Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with a median progression-free survival exceeding three years If approved, Daiichi Sankyo and AstraZeneca’s Enhertu plus pertuzumab would become first new treatment in the EU in more than a decade for first-line HER2 positive metastatic breast cancer Enhertu® (trastuzumab deruxtecan) in combination with pertuzumab has been recommended for approval in the European Union (EU) for the first-line treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP)
SLB Announces Second-Quarter 2026 Results24.7.2026 12:50:00 CEST | Press release
Revenue of $8.97 billion increased 3% sequentially and 5% year on year GAAP EPS of $0.52 increased 4% sequentially and decreased 30% year on year EPS, excluding charges and credits, of $0.55 increased 6% sequentially and decreased 26% year on year Net income attributable to SLB of $786 million increased 5% sequentially and decreased 22% year on year Adjusted EBITDA of $1.90 billion increased 7% sequentially and decreased 7% year on year Cash flow from operations was $1.36 billion and free cash flow was $716 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the second-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722694386/en/ The exterior of the SLB headquarters in Houston, Texas.Second-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeJun. 30, 2026Mar. 31, 2026Jun. 30, 2025SequentialYear-on-yearRevenue $8,972 $8
NIQ Expands GenAI Capabilities Across gfknewron, Turning Trusted Intelligence into Decisions Faster24.7.2026 12:30:00 CEST | Press release
New capabilities help businesses uncover trends faster, simplify complex analysis, and accelerate confident decision-making NIQ (NYSE: NIQ), a leader in consumer intelligence, today announced the expansion of AI-powered Smart Insights across its gfknewron® platform. By bringing together markets and categories into a single view, gfknewron enables businesses to transform complex market, consumer and supply chain data into clear, actionable intelligence quickly. The latest enhancements help users identify trends, opportunities and performance drivers more quickly, reducing the time required to analyze large datasets and accelerating confident decision-making across teams. As brands and retailers face growing pressure to respond quickly to changing consumer behavior and market dynamics, the ability to unlock meaningful insights from increasingly rich datasets has become a significant competitive advantage. As AI is only as effective as the intelligence behind it, Smart Insights helps busi
Thales to Strengthen Romania’s Airspace Protection With Twelve Ground Master 200 MM/A Radars24.7.2026 10:05:00 CEST | Press release
The Romanian General Directorate for Armaments and the French Direction Générale de l’Armement (DGA – the French defence procurement agency) have signed an agreement to supply twelve Thales GM200 Multi-Mission All-in-one (GM200 MM/A) radars to protect the Romanian airspace. This government-to-government agreement underlines the high level of partnership between France and Romania, within the framework of the European Union’s SAFE funding programme, in order to bolster Europe’s defence capabilities. The GM200 MM/A is part of Thales’ proven Ground Master radar family, which has already been deployed in over 40 countries, including now in Romania. In a context of growing collaboration between European nations to bolster collective security, the Romanian General Directorate for Armaments has just signed a landmark agreement with France’s Direction Générale de l’Armement (DGA) to acquire twelve Thales Ground Master 200 Multi-Mission All-in-one (GM200 MM/A) radars. This government-to-governm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom